Skip to content

Absci Corp

US · ABSI #2817 by market cap Listed 2021
9.22 -1.05 -10.22%
Live - 5344 symbols - heartbeat 319s ago · 2026-10-08 07:34
Pre-market 9.13 -1.00%
After-hours 9.25 +0.33%
Overnight 9.23 +0.11%
Market cap
1.58B
P/B
6.43
EPS
-0.84
Reader sentiment Are you bullish or bearish on ABSI?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 7.16 Expensive vs history 97th percentile
5-year average 1.95 · #427 of 514 in Biotechnology
P/E ratio -13.00 Cheap vs history 3rd percentile
5-year average -3.92 · forward -13.63
P/S ratio 1,129.07 Expensive vs history 100th percentile
5-year average 152.74 · forward 204.32 · #348 of 388 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Absci Corp (ABSI) 1.58B -11.67 6.43 0.00%
Vertex Pharmaceuticals (VRTX) 128.16B 29.45 6.33 0.00%
Moderna (MRNA) 78.44B -24.62 11.60 0.00%
Regeneron Pharmaceuticals (REGN) 76.40B 18.36 2.41 0.49%
argenx SE (ARGX) 58.39B 35.37 6.94 0.00%
Revolution Medicines (RVMD) 43.05B -22.65 16.52 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value7.57 Economic moatNone UncertaintyExtreme

Trading 17.9% above Morningstar's fair value estimate.

Fair value

Absci Corp is assigned a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 52% premium over our quantitative fair value estimate of $7.57 per share; however, this estimate should be taken with a pinch of salt due to its extreme uncertainty rating.

The company's lack of profitability decreases our fair value estimate. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. For example, the firm's sales yield falls in the bottom 1% globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which contributes to our view that shares are overvalued.

Conversely, the company's balance sheet is reassuring. Low leverage mitigates financial risk, potentially boosting a firm's value. The firm's current ratio of 10.6, a core component of leverage, falls in the top 10% compared with global peers. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which, despite our unfavorable price/fair value ratio, is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 07:34:47 · For reference only, not investment advice and not tailored to your situation.